Please wait a minute...

中国生物工程杂志

CHINA BIOTECHNOLOGY
中国生物工程杂志  2016, Vol. 36 Issue (10): 115-121    DOI: 10.13523/j.cb.20161016
讲座     
细胞药物的标准及质量控制——细胞药物连载之四
王佃亮
中国人民解放军火箭军总医院药学部组织工程与再生医学实验室 北京 100088
The Standards and Quality Control of Cell Drug
WANG Dian-liang
Tissue Engineering and Regenerative Medicine Laboratory, The General Hospital of The PLA Rocket Force, Beijing 100088, China
 全文: PDF(444 KB)   HTML
摘要:

细胞药物最终用于人体,必须建立相应的质量标准,进行质量控制。系统地贯彻到供者筛查、组织采集、细胞分离、培养、冻存、复苏、放行、运输、使用等全过程,确保产品的安全性、有效性和稳定性。近年来,我国逐渐改变了把细胞治疗作为第三类医疗技术管理的思路。一方面,已有第三类医疗技术取消行政审批;另一方面,又把除自体外的干细胞移植纳入药物管理,并建立了相应的质量标准和质量管理办法。

关键词: 质量标准干细胞第三类医疗技术质量管理细胞药物质量控制    
Abstract:

Cell drugs are eventually used in the human body, it is necessary to establish corresponding standards for quality control. To ensure the safety, effectiveness and stability of the product, the whole process of donor screening,tissue collection, cell separation, cell culture, cell cryopreservation, cell resuscitation, check out, transport and application must be systematically carried out. In recent years, China has gradually changed the management ideas of treating the cell therapy as the third level medical technology. On the one hand, the administrative examination and approval of already existing third level medical technology are currently cancelled. And on the other hand, stem cell transplantations are managed as drug except for autologous stem cell transplantation, and the corresponding standards and management method of quality have already been established.

Key words: Quality control    the third level medical technology    Quality standards    Stem cell    Cell drug    Quality administration
收稿日期: 2016-02-18 出版日期: 2016-03-02
ZTFLH:  Q819  
通讯作者: 王佃亮,电子信箱:wangdianliang@sina.com     E-mail: wangdianliang@sina.com
服务  
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章  
王佃亮

引用本文:

王佃亮. 细胞药物的标准及质量控制——细胞药物连载之四[J]. 中国生物工程杂志, 2016, 36(10): 115-121.

WANG Dian-liang. The Standards and Quality Control of Cell Drug. China Biotechnology, 2016, 36(10): 115-121.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20161016        https://manu60.magtech.com.cn/biotech/CN/Y2016/V36/I10/115

[1] Domen J, Christensen J L, Gille D, et al.Cryopreserved ex vivo-expanded allogeneic myeloid progenitor cell product protects neutropenic mice from a lethal fungal infection. Cell Transplant,2016,25(1):17-33.
[2] Dergacheva T I, Lykov A P, Shurlygina A V, et al. Parameters of microcirculation in the broad ligament of the uterus in Wistar rats after injection of autologous biomedical cell product. Bull Exp Biol Med, 2015,159(6):786-788.
[3] Zhang W, Smythe J, Frith E, et al.An innovative method to generate a good manufacturing practice-ready regulatory T-cell product from non-mobilized leukapheresis donors.Cytotherapy,2015,17(9):1268-1279.
[4] Bachier C, Potter J, Potter G, et al.High white blood cell concentration in the peripheral blood stem cell product can induce seizures during infusion of autologous peripheral blood stem cells. Biol Blood Marrow Transplant, 2012, 18(7):1055-1060.
[5] Lasala G P, Silva J A, Minguell J J. Therapeutic angiogenesis in patients with severe limb ischemia by transplantation of a combination stem cell product. J Thorac Cardiovasc Surg, 2012,144(2):377-382.
[6] Wright C, Velickovic Z, Brown R, et al. Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products.Pathology,2014,46(3):177-183.
[7] Jones M, Varella-Garcia M, Skokan M, et al. Genetic stability of bone marrow-derived human mesenchymal stromal cells in the Quantum System.Cytotherapy, 2013,15(11):1323-1339.
[8] Dominici M, Le Blanc K, Slaper-Cortenbach I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy,2006,8:315-331.
[9] Volpe G, Delibato E, Fabiani L, et al. Development and evaluation of an ELIME assay to reveal the presence of Salmonella in irrigation water: comparison with real-time PCR and the standard culture method. Talanta, 2016,149:202-210.
[10] Dufrane D, Docquier P L, Delloye C, et al. Scaffold-free three-dimensional graft from autologous adipose-derived stem cells for large bone defect reconstruction: Clinical proof of concept.Medicine (Baltimore),2015,94(50):e2220.
[11] Montemurro T, Viganò M, Budelli S, et al.How we make cell therapy in Italy. Drug Des Devel Ther,2015,9:4825-4834.
[12] Elseberg C L, Salzig D, Czermak P. Bioreactor expansion of human mesenchymal stem cells according to GMP requirements. Methods Mol Biol,2015,1283:199-218.
[13] Gastens M H, Goltry K, Prohaska W, et al. Good manufacturing practice-compliant expansion of marrow-derived stem and progenitor cells for cell therapy.Cell Transplant,2007,16(7):685-696.
[14] Mijovic A, Pamphilon D.Harvesting, processing and inventory management of peripheral blood stem cells. Asian J Transfus Sci,2007,1(1):16-23.
[15] Cobo F, Stacey G N, Hunt C, et al. Microbiological control in stem cell banks: approaches to standardisation. Appl Microbiol Biotechnol,2005,68(4):456-466.
[16] Wen S H, Zhao W L, Lin P Y, et al. Associations among birth weight, placental weight, gestational period and product quality indicators of umbilical cord blood units.Transfus Apher Sci,2012,46(1):39-45.
[17] Ilic N, Brooke G, Murray P, et al. Manufacture of clinical grade human placenta-derived multipotent mesenchymal stromal cells. Methods Mol Biol,2011,698:89-106.
[18] Spohn G, Wiercinska E, Karpova D, et al. Automated CD34+ cell isolation of peripheral blood stem cell apheresis product.Cytotherapy,2015,17(10):1465-1471.
[19] Angbohang A, Wu N, Charalambous T, et al.Downregulation of the canonical WNT signaling pathway by TGFβ1 inhibits photoreceptor differentiation of adult human Müller Glia with stem cell characteristics.Stem Cells Dev, 2016,25(1):1-12.
[20] Lei M, Li K, Li B, et al. Mesenchymal stem cell characteristics of dental pulp and periodontal ligament stem cells after in vivo transplantation. Biomaterials,2014,35(24):6332-6343.
[21] Nicolay N H, Sommer E, Lopez R, et al.Mesenchymal stem cells retain their defining stem cell characteristics after exposure to ionizing radiation. Int J Radiat Oncol Biol Phys, 2013,87(5):1171-1178.

[1] 钱昱,丁晓雨,刘志强,袁增强. 基因修饰人多能干细胞的高效单克隆建系方法[J]. 中国生物工程杂志, 2021, 41(8): 33-41.
[2] 李开秀,司维. 间充质干细胞来源的外泌体治疗炎症性肠病研究进展*[J]. 中国生物工程杂志, 2021, 41(7): 66-73.
[3] 王宇轩,陈婷,张永亮. MiR-148生物学功能研究进展*[J]. 中国生物工程杂志, 2021, 41(7): 74-80.
[4] 赵久梅,王哲,李学英. 调控软骨形成的信号通路及相关因子在骨髓间充质干细胞骨向分化中的作用*[J]. 中国生物工程杂志, 2021, 41(10): 62-72.
[5] 陈飞,王晓冰,徐增辉,钱其军. 干细胞改善糖尿病的分子机制及临床研究进展[J]. 中国生物工程杂志, 2020, 40(7): 59-69.
[6] 戴奇男,张景红. 肿瘤多药耐药与自噬、DNA修复和肿瘤干细胞相关的分子机制研究进展 *[J]. 中国生物工程杂志, 2020, 40(4): 69-77.
[7] 苑亚坤,刘广洋,刘拥军,谢亚芳,吴昊. 间充质干细胞基础研究与临床转化的中美比较[J]. 中国生物工程杂志, 2020, 40(4): 97-107.
[8] 杨丹,田海山,李校堃. 成纤维细胞生长因子5的研究进展 *[J]. 中国生物工程杂志, 2020, 40(3): 117-124.
[9] 李玉,张晓. 日本细胞治疗监管双轨制的经验及启示 *[J]. 中国生物工程杂志, 2020, 40(1-2): 174-179.
[10] 陈利军,屈晶晶,项春生. 间充质干细胞在2019新型冠状病毒肺炎(COVID-19)中的治疗潜能、临床研究与应用前景*[J]. 中国生物工程杂志, 2020, 40(11): 43-55.
[11] 邱丹丹,陆彩霞,代解杰. 诱导多能干细胞来源的肝细胞在HCV感染模型中的应用*[J]. 中国生物工程杂志, 2020, 40(11): 67-72.
[12] 朱永朝,陶金,任萌萌,熊燃,何亚琴,周瑜,卢震辉,杜勇,杨芝红. 自噬抑制肿瘤坏死因子α诱导人胎盘胎儿来源间充质干细胞发生凋亡 *[J]. 中国生物工程杂志, 2019, 39(9): 62-67.
[13] 李欣,赵中利,罗晓彤,曹阳,张立春,于永生,金海国. 诱导多能干细胞向雄性生殖细胞分化诱导物的研究进展 *[J]. 中国生物工程杂志, 2019, 39(4): 94-100.
[14] 刘国芳,刘晓志,高健,王志明. 宿主细胞残留蛋白质对单克隆抗体药物质量影响及其质量控制 *[J]. 中国生物工程杂志, 2019, 39(10): 105-110.
[15] 范月蕾,陆娇,陈大明,毛开云. 干细胞专利价值评估与转移转化对策研究 *[J]. 中国生物工程杂志, 2019, 39(1): 99-106.